Ponezumab

Source: Wikipedia, the free encyclopedia.
Ponezumab
beta-amyloid
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6552H10158N1730O2090S52
Molar mass148272.48 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Ponezumab is a humanized monoclonal antibody designed for the treatment of Alzheimer's disease.[1][2]

Ponezumab was developed by Pfizer Inc. In November 2011 Pfizer halted the development of ponezumab after finishing a phase 2 trial.[3]

References

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ponezumab" (PDF). American Medical Association.
  2. ISBN 978-1-68108-068-0
    .
  3. ^ "Alzforum".
Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Ponezumab&oldid=1190949800"